The case scenario handles Gilead Sciences; a bio-pharmaceutical organization along with numerous FDA gave consent to HIV/AIDS drugs. In the year 2006, the business launched the Gilead Access Program to improve accessibility to HIV/AIDS drugs in developing countries. In India, which at the same time happened to be the largest manufacturer of generic drugs, Gilead signed a voluntary licensing agreement for its drug, Viread, with 13 firms.By year 2011, Mylan (formerly known as Matrix Laboratories), among the 13 Indian firms, had materialized as the top supplier for Viread, with two-thirds of the global market. In order to hasten its market reach, Gilead needed to expand the extent of the agreement with four leading Indian businesses, comprising Mylan. Gregg Alton, the Executive Vice President for the Corporate and Medical Affairs must choose how he had assured his partners to come on board and the way to execute the agreement.
PUBLICATION DATE: June 30, 2013 PRODUCT #: ISB025-PDF-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
Passion for Learning
Health Stop (B): The Medical Offices
Hutton Branch Manager (B)
Nutra Foods
Warner Cable (B)
APPLE INC. IN 2015
Kimberly-Clark Andean Region: Creating a Winning Culture
SIAM PARK CITY: CAN AFFORDABLE PRICING BE PROFITABLE?
BREADTALK: CONTINUOUS INNOVATION TO KEEP THE BRAND FRESH
SONIC RESTAURANTS: DOES ITS DRIVE-IN BUSINESS MODEL LIMIT FUTURE GROWTH POTENTIAL?
